684 related articles for article (PubMed ID: 30639820)
1. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
2. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
3. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
4. Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.
Schoettler M; Duncan C; Lehmann L
Pediatr Transplant; 2019 May; 23(3):e13381. PubMed ID: 30828947
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Genere L; Bacchetta J; Bertrand Y; Javouhey E; Cheikh N; Sellier-Leclerc AL
Arch Pediatr; 2018 Nov; 25(8):485-488. PubMed ID: 30340942
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
Tolbert VP; Dvorak CC; Golden C; Vissa M; El-Haj N; Perwad F; Matthay KK; Vo KT
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2031-2039. PubMed ID: 31199983
[TBL] [Abstract][Full Text] [Related]
9. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
10. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
11. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab in Transplant-Associated Thrombotic Microangiopathy.
Dhakal P; Giri S; Pathak R; Bhatt VR
Clin Appl Thromb Hemost; 2017 Mar; 23(2):175-180. PubMed ID: 26259912
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
14. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?
Jodele S; Laskin BL; Goebel J; Khoury JC; Pinkard SL; Carey PM; Davies SM
Transfusion; 2013 Mar; 53(3):661-7. PubMed ID: 22804695
[TBL] [Abstract][Full Text] [Related]
15. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.
Schoettler ML; Carreras E; Cho B; Dandoy CE; Ho VT; Jodele S; Moissev I; Sanchez-Ortega I; Srivastava A; Atsuta Y; Carpenter P; Koreth J; Kroger N; Ljungman P; Page K; Popat U; Shaw BE; Sureda A; Soiffer R; Vasu S
Transplant Cell Ther; 2023 Mar; 29(3):151-163. PubMed ID: 36442770
[TBL] [Abstract][Full Text] [Related]
16. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Manifestations and Vascular Changes in Pediatric Transplantation-Associated Thrombotic Microangiopathy.
Schoettler ML; Saldana BD; Berkenkamp L; Chonat S; Watkins B; Rotz SJ; Simons D; Graf E; Rossi C; Cheng J; Hammers YA; Rytting H; Williams KM
Transplant Cell Ther; 2023 Jan; 29(1):45.e1-45.e8. PubMed ID: 36202334
[TBL] [Abstract][Full Text] [Related]
18. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Plasma Exchange does not Improve Renal Function in Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: An Institutional Experience.
Sartain S; Shubert S; Wu MF; Srivaths P; Teruya J; Krance R; Martinez C
Biol Blood Marrow Transplant; 2019 Jan; 25(1):157-162. PubMed ID: 30144562
[TBL] [Abstract][Full Text] [Related]
20. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]